Source comparison
The Pituitary Receptor Mechanism: GHRH vs Ghrelin Pathways
CJC-1295 No DAC is a 29-amino-acid analog of growth hormone-releasing hormone (GHRH), modified at positions 2, 8, 15, and 27 to resist enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV). GHRH naturally binds to GHRH receptors on somatotroph cells in the
This comparison does not assign a generated winner or score.
- CJC-1295 No DAC is a 29-amino-acid analog of growth hormone-releasing hormone (GHRH), modified at positions 2, 8, 15, and 27 to resist enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV). GHRH naturally binds to GHRH receptors on somatotroph cells in the anterior pituitary, triggering cAMP-mediated GH secretion. The 'No DAC' designation indicates the absence of Drug Affinity Complex. A modification that would extend half-life to 6–8 days but flatten pulsatility. Without DAC, CJC-1295 has a half-life of approximately 30 minutes, allowing it to amplify a single GH pulse (lasting 2–4 hours) before clearance. Each dose creates one extended pulse. Not continuous elevation.
- Ipamorelin operates through a completely different pathway. It's a pentapeptide ghrelin mimetic that binds selectively to the GHS-R1a receptor (growth hormone secretagogue receptor type 1a) without activating cortisol or prolactin pathways. Early secretagogues like GHRP-2 and GHRP-6 bind less selectively, triggering cortisol spikes of 20–40% above baseline and prolactin elevation. Ipamorelin does neither. This selectivity makes it the preferred ghrelin analog in research contexts where cortisol interference would confound metabolic or body composition outcomes. Ipamorelin's half-life is approximately 2 hours, creating a sharp, intense pulse that peaks 20–30 minutes post-administration and clears within 4 hours.
- When dosed together, CJC-1295 No DAC extends the pulse duration while ipamorelin amplifies pulse intensity. The result is a GH secretion pattern closer to natural physiology than either peptide alone. Avoiding the receptor desensitization seen with continuous exogenous GH while producing IGF-1 elevations sufficient to drive measurable anabolic and lipolytic outcomes.